Abstrakt

Insulin-like growth factor-binding protein 7 (IGFBP7) is a 30kDa modular secreted protein involved in many physiologic processes, including cell proliferation, adhesion, senescence and angiogenesis. It is expressed in many organs and specific cells. It can interact with insulin-like growth factor 1(IGF-1), as well as with insulin. By binding to IGF-1, it limits IGF-1 access to IGF- receptor (IGF-R) and consequently neutralizes IGF-1 activity. Moreover, due to its high affinity to insulin, it may interfere with biological response of insulin and, therefore, it may be involved in the development of diabetes and cardiovascular diseases. According to research, it could be a good biomarker of heart failure. Its elevated serum concentrations were found in patients with heart failure, both with reduced ejection fraction and preserved ejection fraction. Moreover, IGFBP7 could be useful in predicting the presence of atherosclerotic lesions in coronary vessels, although its concentration does not reflect a degree of coronary artery disease (CAD) advancement and it cannot be used as a marker of acute ischemia. Its concentration is also associated with insulin resistance and the risk of metabolic syndrome. What is more, together with tissue inhibitor of metalloproteinases-2, it is a novel marker of tubular damage and it can be used for an early detection of acute kidney injury (AKI) endangered patients, which could allow for subsequent adjustments in medical therapy and the prevention of AKI. IGFBP7 is also regarded as a potential tumor suppressor in various cancers. Its low expression is potentially correlated with increased cancer cell proliferation.

Przypisy

• 1. An W., Ben Q.W., Chen H.T., Zheng J.M., Huang L., Li G.X., LiZ.S.: Low expression of IGFBP7 is associated with poor outcomeof pancreatic ductal adenocarcinoma. Ann. Surg. Oncol., 2012;19: 3971–3978
  Google Scholar
• 2. Aregger F., Uehlinger D.E., Witowski J., Brunisholz R.A., HunzikerP., Frey F.J., Jörres A.: Identification of IGFBP-7 by urinary proteomicsas a novel prognostic marker in early acute kidney injury. KidneyInt., 2014; 85: 909–919
  Google Scholar
• 3. Barroso M.C., Kramer F., Greene S.J., Scheyer D., Köhler T., KaroffM., Seyfarth M., Gheorghiade M., Dinh W.: Serum insulin-like growthfactor-1 and its binding protein-7: potential novel biomarkers forheart failure with preserved ejection fraction. BMC Cardiovasc. Disord.,2016; 16: 199
  Google Scholar
• 4. Chen D., Yoo B.K., Santhekadur P.K., Gredler R., Bhutia S.K., DasS.K., Fuller C., Su Z.Z., Fisher P.B., Sarkar D.: Insulin-like growthfactor binding protein-7 (IGFBP-7) functions as a potential tumorsuppressor in hepatocellular carcinoma (HCC). Clin. Cancer. Res.,2011; 17: 6693–6701
  Google Scholar
• 5. Chugh S., Ouzounian M., Lu Z., Mohamed S., Li W., Bousette N.,Liu P.P., Gramolini A.O.: Pilot study identifying myosin heavy chain 7,desmin, insulin-like growth factor 7, and annexin A2 as a circulatingbiomarkers of human heart failure. Proteomics, 2013; 13: 2324–2334
  Google Scholar
• 6. Degeorges A., Wang F., Frierson H.F. Jr, Seth A., Sikes R.A.: Distributionof IGFBP-rP1 in normal human tissues. J. Histochem. Cytochem.,2000; 48: 747–754
  Google Scholar
• 7. Evdokimova V., Tognon C.E., Benatar T., Yang W., Krutikov K.,Pollak M., Sorensen P.H., Seth A.: IGFBP7 binds to the IGF-1 receptorand blocks its activation by insulin-like growth factors. Sci. Signal.,2012; 5: ra92
  Google Scholar
• 8. Gambaro K., Quinn M.C., Caceres-Gorriti K.Y., Shapiro R.S., ProvencherD., Rahimi K., Mes-Masson A.M., Tonin P.N.: Low levels ofIGFBP7 expression in high-grade serous ovaria carcinoma is associatedwith patient outcome. BMC Cancer, 2015; 15: 135
  Google Scholar
• 9. Gandhi P.U., Chow S.L., Rector T.S., Krum H., Gaggin H.K., McMurray J.J., Zile M.R., Komajda M., McKelvie R.S., Carson P.E., Januzzi J.L. Jr, Anand I.S.: Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. J. Card. Fail., 2017; 23: 20–28
  Google Scholar
• 10. Gandhi P.U., Gaggin H.K., Sheftel A.D., Belcher A.M., Weiner R.B.,Baggish A.L., Motiwala S.R., Liu P.P., Januzzi J.L. Jr.: Prognostic usefulnessof insulin-like growth factor-binding protein 7 in heart failurewith reduced ejection fraction: A novel biomarker of myocardialdiastolic function? Am. J. Cardiol., 2014; 114: 1543–1549
  Google Scholar
• 11. Gocze I., Koch M., Renner P., Zeman F., Graf B.M., Dahlke M.H.,Nerlich M., Schlitt H.J., Kellum J.A., Bein T.: Urinary biomarkersTIMP-2 and IGFBP7 early predict acute kidney injury after majorsurgery. PLoS One, 2015; 10: e0120863
  Google Scholar
• 12. Goncharova I.A., Pecherina T.B., Markov A.V., Kashtalap V.V.,Tarasenko N.V., Puzyrev V.P., Barbarash O.L.: Fibrogenesis genes andsusceptibility to coronary atherosclerosis. Kardiologiia, 2018; 8: 33–44
  Google Scholar
• 13. Gu H.F., Gu T., Hilding A., Zhu Y., Kärvestedt L., Ostenson C.G., Lai M., Kutsukake M., Frystyk J., Tamura K., Brismar K.: Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes. Clin. Epigenetics, 2013; 5: 20
  Google Scholar
• 14. Gunnerson K.J., Shaw A.D., Chawla L.S., Bihorac A., Al-Khafaji A., Kashani K., Lissauer M., Shi J., Walker M.G., Kellum J.A., Sapphire Topaz Investigators: TIMP-2*IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients. J. Trauma. Acute Care Surg., 2016; 80: 243–249
  Google Scholar
• 15. Jia H.M., Huang L.F., Zheng Y., Li W.X.: Prognostic value of cellcycle arrest biomarkers in patients at high risk for acute kidneyinjury: A systematic review and meta-analysis. Nephrology, 2017;22: 831–837
  Google Scholar
• 16. Komiya E., Furuya M., Watanabe N., Miyagi Y., Higashi S., MiyazakiK.: Elevated expression of angiomodulin (AGM/IGFBP-rP1)in tumor stroma and its roles in fibroblast activation. Cancer Sci.,2012; 103: 691–699
  Google Scholar
• 17. Li P., Sun X., Cai G., Chen X.: Insulin-like growth factor systemand aging. J. Aging Sci., 2017; 5: 171
  Google Scholar
• 18. Lisowska A., Knapp M., Tycinska A., Swiecki P., Kaminski K.,Musial W.J.: The new biomarker in coronary artery disease – thediagnostic and prognostic value of insulin like growth factor bindingprotein 7 (IGFBP7) and galectin 3 (Gal 3). Eur. Heart J., 2017; 38(Suppl. 1): ehx493.P5865
  Google Scholar
• 19. Lisowska A., Święcki P., Knapp M., Gil M., Musiał W.J., KamińskiK., Hirnle T., Tycinska A.: Insulin-like growth factor-binding protein 7 (IGFBP7) as a new biomarker in coronary heart disease. Adv. Med.Sci., 2019; 64: 195–201
  Google Scholar
• 20. Liu L., Yang Z., Zhang W., Yan B., Gu Q., Jiao J., Yue X.: Decreasedexpression of IGFBP7 was a poor prognosis predictor for gastric cancerpatients. Tumour Biol., 2014; 354: 8875–8881
  Google Scholar
• 21. Liu Y., Wu M., Ling J., Cai L., Zhang D., Gu H.F., Wang H., Zhu Y.,Lai M.: Serum IGFBP7 levels associate with insulin resistance andthe risk of metabolic syndrome in a Chinese population. Sci. Rep.,2015; 5: 10227
  Google Scholar
• 22. Meersch M., Schmidt C., Van Aken H., Martens S., Rossaint J.,Singbartl K., Görlich D., Kellum J.A., Zarbock A.: Urinary TIMP-2 andIGFBP7 as early biomarker of acute kidney injury and renal recoveryfollowing cardiac surgery. PLoS One, 2014; 9: e93460
  Google Scholar
• 23. Motiwala S.R., Szymonifka J., Belcher A., Weiner R.B., BaggishA.L., Gaggin H.K., Bhardwaj A., Januzzi J.L. Jr: Measurement of novelbiomarkers to predict chronic heart failure outcomes and left ventricularremodeling. J. Cardiovasc. Transl. Res., 2014; 7: 250–261
  Google Scholar
• 24. Oezkur M., Magyar A., Thomas P., Stork T., Schneider R., Bening C., Störk S., Heuschmann P.U., Leyh R.G., Wagner M.: TIMP-2*IGFBP7 (Nephrocheck®) measurements at intensive care unit admission after cardiac surgery are predictive for acute kidney injury within 48 hours. Kidney Blood Press. Res., 2017; 42: 456–467
  Google Scholar
• 25. Paulus W.J., Tschöpe C.: A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol., 2013; 62: 263–271
  Google Scholar
• 26. Pilarczyk K., Edayadiyil-Dudasova M., Wendt D., Demircioglu E., Benedik J., Dohle D.S., Jakob H., Dusse F.: Urinary [TIMP-2]*[IGFBP7] for early prediction of acute kidney injury after coronary bypass surgery. Ann. Intensive Care, 2015; 5: 50
  Google Scholar
• 27. Schanz M., Shi J., Wasser C., Alscher M.D., Kimmel M.: Urinary[TIMP-2] x [IGFBP7] for risk prediction of acute kidney injuryin decompensated heart failure. Clin. Cardiol., 2017; 40: 485–491
  Google Scholar
• 28. Severino V., Alessio N., Farina A., Sanomenico A., Cipollaro M.,Peluso G., Galderisi U., Chambery A.: Insulin-like growth factor bindingproteins 4 and 7 released by senescent cells promote prematuresenescence in mesenchymal cells. Cell Death Dis., 2013; 4: e911
  Google Scholar
• 29. Tamura K., Hashimoto K., Suzuki K., Yoshie M., Kutsukake M.,Sakurai T.: Insulin-like growth factor binding protein-7 (IGFBP7)blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesisin human vascular endothelial cells. Eur. J. Pharmacol.,2009; 610: 61–67
  Google Scholar
• 30. van Breevoort D., van Agtmaal E.L., Dragt B.S., Gebbinck J.K.,Dienava-Verdoold I., Kragt A., Bierings R., Horrevoets A.J., ValentijnK.M., Eikenboom J.C., Fernandez-Borja M., Meijer A.B., VoorbergJ.: Proteomic screen identifies IGFBP7 as a novel componentof endothelial cell-specific Weibel-Palade bodies. Proteome Res.,2012; 11: 2925–2936
  Google Scholar
• 31. Verhagen H.J., de Leeuw D.C., Roemer M.G., Denkers F., PouwelsW., Rutten A., Celie P.H., Ossenkoppele G.J., Schuurhuis G.J., Smit L.:IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizeswith chemotherapy in suppression of leukemia cell survival.Cell Death Dis., 2014; 5: e1300
  Google Scholar
• 32. Wang Z., Wang Z., Liang Z., Liu J., Shi W., Bai P., Lin X., MagayeR., Zhao J.: Expression and clinical significance of IGF-1, IGFBP-3and IGFBP-7 in serum and lung cancer tissues from patients withnon-small cell lung cancer. Onco. Targets Ther., 2013; 6: 1437–1444
  Google Scholar
• 33. Wasung M.E., Chawla L.S., Madero M.: Biomarkers of renal function,which and when? Clin. Chim. Acta, 2015; 438: 350–357
  Google Scholar
• 34. Watanabe J., Takiyama Y., Honjyo J., Makino Y., Fujita Y., TatenoM., Haneda M.: Role of IGFBP7 in diabetic nephropathy: TGF-β1 inducesIGFBP7 via Smad2/4 in human renal proximal tubular epithelialcells. PLoS One, 2016; 11: e0150897
  Google Scholar
• 35. Wetz A.J., Richardt E.M., Wand S., Kunze N., Schotola H., QuintelM., Bräuer A., Moerer O.: Quantification of urinary TIMP-2 andIGFBP-7: an adequate test to predict acute kidney injury after cardiacsurgery? Crit. Care, 2015; 19: 3
  Google Scholar
• 36. Yue C., Yang M., Tian Q., Mo F., Peng J., Ma Y., Huang Y., WangD., Wang Y., Hu Z.: IGFBP7 is associated to prognosis and could suppresscell survival in cholangiocarcinoma. Artif. Cells Nanomed.Biotechnol., 2018; 46: 817–825
  Google Scholar

Pełna treść artykułu